Audited Standalone and Consolidated Financial Results for the Quarter and Year Ended 31st March, 2026
INDOCO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 5.3 pts more than Nifty Microcap 250 and 6.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Indoco Remedies reported standalone Q4 FY26 revenue of Rs 42,906 lakhs, up 26% year-on-year, with the company returning to profit (PAT Rs 2,735 lakhs vs loss of Rs 2,624 lakhs in Q4 FY25). For the full year, standalone revenue grew 9.3% to Rs 1,63,354 lakhs but the company still posted a net loss of Rs 566 lakhs (vs loss of Rs 873 lakhs in FY25). Consolidated revenue for FY26 was Rs 1,79,294 lakhs, up 9.2% YoY, but consolidated net loss widened to Rs 9,870 lakhs from Rs 7,795 lakhs. Finance costs nearly doubled year-on-year (standalone: Rs 8,850 vs Rs 5,663 lakhs). The auditors issued an unmodified opinion but included an Emphasis of Matter regarding FPP Holding LLC, a US subsidiary with negative net worth of Rs 8,225 lakhs and net loss of Rs 2,365 lakhs, raising going concern doubts. The board recommended a dividend of Rs 0.20 per share.
The company shows revenue growth but widening consolidated losses and elevated finance costs are concerns. The auditor's going concern flag on the FPP Holding subsidiary adds risk, though the main entity remains profitable at standalone level. The small dividend payout signals limited cash flexibility.